Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1

(2013) D M Moujalled et al.   Cell Death & Disease

Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1

(2012) ZhenZhen Zhan et al.   Autophagy

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

(2012) D. Wroblewski et al.   CARCINOGENESIS

Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase

(2012) Liming Sun et al.   CELL

The Mitochondrial Phosphatase PGAM5 Functions at the Convergence Point of Multiple Necrotic Death Pathways

(2012) Zhigao Wang et al.   CELL

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma

(2012) Y Shao et al.   CELL DEATH AND DIFFERENTIATION

Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models

(2012) P Vandenabeele et al.   CELL DEATH AND DIFFERENTIATION

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

(2012) K. H. T. Paraiso et al.   CLINICAL CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Melanoma: New Insights and New Therapies

(2012) Vasiliki A. Nikolaou et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

NF-κB as potential target in the treatment of melanoma

(2012) Gabriele Madonna et al.   Journal of Translational Medicine

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

(2012) N Takahashi et al.   Cell Death & Disease

NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-α Feedforward Signaling

(2011) Sharon Biton et al.   CELL

PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration

(2011) Ganta Chaitanya et al.   Cell Communication and Signaling

Many stimuli pull the necrotic trigger, an overview

(2011) N Vanlangenakker et al.   CELL DEATH AND DIFFERENTIATION

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress

(2011) L Dong et al.   ONCOGENE

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation

(2011) YoungSik Cho et al.   PLoS One

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720

(2010) C. C. Jiang et al.   CLINICAL CANCER RESEARCH

Necroptosis as an alternative form of programmed cell death

(2010) Dana E Christofferson et al.   CURRENT OPINION IN CELL BIOLOGY

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

(2010) Mark Andrew Dickson et al.   INVESTIGATIONAL NEW DRUGS

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

(2010) Jonas N Søndergaard et al.   Journal of Translational Medicine

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

(2010) Keiran S.M. Smalley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS

(2010) C C Jiang et al.   Cell Death & Disease

A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

(2009) A Rocca et al.   BRITISH JOURNAL OF CANCER

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

(2009) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

(2009) Axel Hauschild et al.   MELANOMA RESEARCH

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Molecular Signaling Network that Regulates a Cellular Necrotic Cell Death Pathway

(2008) Junichi Hitomi et al.   CELL

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology